What's Happening?
Lonza has agreed to provide cGMP manufacturing and technical support for the commercial scale production of RION's Purified Exosome Product™ (PEP) drug substance. RION's proprietary biomanufacturing platform enables scaled production of platelet-derived exosomes, advancing its pipeline of exosome-based therapeutics across multiple indications. Lonza will manufacture the PEP™ drug substance at its facility in Houston, leveraging its expertise in extracellular vesicle technologies to operationalize RION's process at scale.
Why It's Important?
Exosome-based therapeutics represent a promising area in regenerative medicine, offering potential treatments for conditions such as musculoskeletal disease, pulmonary disease, and cardiovascular health. The collaboration with Lonza ensures that RION's manufacturing platform can meet clinical and future commercial demand, potentially accelerating the availability of innovative treatments to patients. This partnership highlights the growing interest in biologics-based therapies and the importance of scalable manufacturing solutions in bringing new medical innovations to market.
